Deltex Medical Group PLC Grant of options (0518C)
February 17 2022 - 10:02AM
UK Regulatory
TIDMDEMG
RNS Number : 0518C
Deltex Medical Group PLC
17 February 2022
17 February, 2022
Deltex Medical Group plc
("Deltex Medical" or the "Group")
Grant of options
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), announces that yesterday,
16 February 2022, the Board approved the issue of share options to
Andy Mears, Chief Executive Officer and Natalie Wettler, Group
Finance Director, under the Company's 2003 Share Option Scheme (the
"EMI Share Scheme").
Employee Share Option Scheme
In accordance with the Company's Renumeration Policy the Board
has approved the issue of 15,000,000 share options to Andy Mears,
Chief Executive and 8,500,000 share options to Natalie Wettler,
Group Finance Director. The exercise price for these options is
1.35 pence per share, the closing price on 16 February 2022. These
share options will vest three years after award, subject to
performance conditions based on achieving certain specified
earnings targets, or in the event of a change in control of the
Company.
Confirmation of Directors' interests in share options
Following the grant of EMI options above, the options held by
Directors are shown below:
Executive Director 2011 Executive Share Scheme 2003 EMI Share Scheme Total
Number Number Number
Andy Mears 150,000 25,000,000 25,150,000
Natalie Wettler - 11,250,000 11,250,000
For further information, please contact:
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman investorinfo@Deltexmedical.com
Andy Mears, Chief Executive
Natalie Wettler, Group Finance Director
Arden Partners plc 020 7614 5900
Paul Shackleton (Corporate Finance)
Simon Johnson (Corporate Broking)
Joint Broker
Turner Pope Investments (TPI) Ltd 0203 657 0050
Andy Thacker info@turnerpope.com
James Pope
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name a. Andy Mears (Chief Executive)
b. Natalie Wettler (Group Finance Director)
-------------------------- -------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status See 1 a) above
-------------------------- -------------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- -------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Deltex Medical Group plc
-------------------------- -------------------------------------------------
b) LEI 213800XN34P6LI8J6M39
-------------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of the Issue of share options
financial instrument,
type of instrument Identification code (ISIN) for Deltex
Identification code Medical Group plc ordinary shares: GB0059337583
-------------------------- -------------------------------------------------
b) Nature of the transaction Issue of options
-------------------------- -------------------------------------------------
c) Price(s) and volume(s) Issue of share options
a. 23,500,000
-------------------------- -------------------------------------------------
d) Aggregated information
- Aggregated volume 23,500,000
- Price Exercisable at 1.35 pence
-------------------------- -------------------------------------------------
e) Date of the transaction 17.02.22
-------------------------- -------------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- -------------------------------------------------
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies, which are primarily used in critical care and general
surgical procedures. Deltex Medical's proprietary oesophageal
Doppler monitoring (TrueVue Doppler) measures blood flow velocity
in the central circulation in real time. The technology generates a
low-frequency ultrasound signal which is highly sensitive to
changes in blood flow and measures such changes in 'real time'.
Deltex Medical is the only company in the enhanced haemodynamic
monitoring space to have built a robust and credible evidence base
demonstrating both the clinical and economic benefits of its core
technology: TrueVue Doppler. This technology has been proven in a
wide range of clinical trials to reduce complications suffered by
patients after surgery and consequently can save hospitals
money.
Clinicians would like to be able to monitor the haemodynamic
status of awake patients not only in the operating room and
intensive care departments. Our R&D programmes will provide the
capability for Deltex Medical devices to be used in A&E,
including, for example, for the rapid detection of sepsis, as well
as on lower acuity wards or outside the hospital setting.
Deltex Medical is designing the next generation of non-invasive
Doppler ultrasound devices that will be released onto the TrueVue
platform and will accurately measure a non-sedated patient's
haemodynamic status anywhere within the hospital and not just for
elective surgical patients.
Group goal
Haemodynamic management is now becoming widely accepted as a
vital part of the anaesthesia protocols for surgical patients, as
well as treating ventilated intensive care patients, including
ventilated COVID-19 patients. There is also a desire to start
measuring haemodynamics on awake patients outside of the operating
room or intensive care departments, such as in lower acuity units
or in A&E. Our R&D programmes are targeting these broader
applications. Consequently, the Group's focus is on maximising
value from the opportunities associated with: the COVID-19
pandemic; the elective surgery backlog; the risks associated with
sepsis; awake patients and the higher profile of haemodynamic
monitoring which has arisen from recent consolidation in the
sector.
The Group aims to provide clinicians with a modern, next
generation, single 'haemodynamic workstation' platform which offers
them a range of technologies from simple to sophisticated to be
deployed according to the patient's clinical condition as well as
the skill and expertise of the user. Doing this will enable the
Group to partner with healthcare providers to support modern
haemodynamic management across the whole hospital.
The Group is currently in the implementation phase of achieving
this goal in a number of territories worldwide, operating directly
in the UK and the USA, and via agreements with approximately 40
distributors overseas.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFEEFAIDLIF
(END) Dow Jones Newswires
February 17, 2022 11:02 ET (16:02 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024